Table 3 Rate of responding patients according to baseline characteristics
From: Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
Variable | no. of patients | response rate | |
|---|---|---|---|
| Â | at risk | responding | (95% exact CI) |
Age | Â | Â | Â |
   <65 | 40 | 21 | 52.5 (36.1–68.5) |
   65 or more | 10 | 3 | 30.0 (6.7–65.2) |
Histotype | Â | Â | Â |
   Ductal | 41 | 20 | 48.8 (32.9–64.9) |
   Lobular or other | 9 | 4 | 44.4 (13.7–78.8) |
ER status | Â | Â | Â |
   Negative | 19 | 9 | 47.4 (24.5–71.1) |
   Positive | 30 | 14 | 46.7 (28.3–65.7) |
Performance status | Â | Â | Â |
   0 | 41 | 22 | 53.7 (37.4–69.3) |
   1 or 2 | 9 | 2 | 22.2 (2.8–60.0) |
Time from breast cancer diagnosis | Â | Â | Â |
   <2 years | 19 | 12 | 63.2 (38.4–83.7) |
   2 years or more | 31 | 12 | 38.7 (21.8–57.8) |
Previous chemotherapy | Â | Â | Â |
   No | 9 | 4 | 44.4 (13.7–78.8) |
   Yes | 41 | 20 | 48.8 (32.9–64.9) |
By type of drugs | Â | Â | Â |
CMF | 4 | 2 | 50.0 (6.8–93.2) |
with anthracycline | 24 | 13 | 54.2 (32.8–74.5) |
with anthracycline and taxane | 13 | 5 | 38.5 (13.9–68.4) |
By number of lines of chemotherapy | Â | Â | Â |
one line | 26 | 13 | 50.0 (29.9–70.1) |
two lines | 15 | 7 | 46.7 (21.3–73.4) |
Extension of disease | Â | Â | Â |
   By number of involved organs |  |  |  |
1 | 27 | 13 | 48.1 (28.7–68.0) |
2 | 16 | 7 | 43.7 (19.7–70.1) |
3 | 7 | 4 | 57.1 (18.4–90.1) |
   By dominant metastatic site |  |  |  |
soft tissues | 13 | 7 | 53.8 (25.1–80.8) |
viscera | 37 | 17 | 45.9 (29.5–63.1) |